cAMP-guanine exchange factor protection from bile acid-induced hepatocyte apoptosis involves glycogen synthase kinase regulation of c-jun NH2-terminal kinase

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 301, Issue 2, 2011, Pages

  Johnston, A ^a   Ponzetti, K ^a   Anwer, M S ^a   Webster, C R L ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Cholestasis; Endoplasmic reticulum stress; EPAC; Phosphoinositide 3 kinase; Rap

Indexed keywords

BILE ACID; CYCLIC AMP; CYCLIC AMP DERIVATIVE; GLYCOCHENODEOXYCHOLIC ACID; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; MALEIMIDE DERIVATIVE; OXIME DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAP1 PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; THIADIAZOLE DERIVATIVE;

ADENOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; BILE ACIDS AND SALTS; CARCINOMA, HEPATOCELLULAR; CYCLIC AMP; CYTOPROTECTION; ENDOPLASMIC RETICULUM; GLYCOCHENODEOXYCHOLIC ACID; GLYCOGEN SYNTHASE KINASE 3; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEPATOCYTES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RAP1 GTP-BINDING PROTEINS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TUMOR CELLS, CULTURED;

EID: 79960997015     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00430.2010     Document Type: Article

References (98)

1. Aghdam SY, Barger SW. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr Alzheimer Res 4: 21-31, 2007.
2. Avila J, Wandosell F, Hernaacute;ndez F. Role of glycogen synthase kinase-3 in Alzheimers disease: pathogenesis and glycogen kinase-3 inhibitors. Expert Rev Neurother 10: 703-710, 2010.
3. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315, 2007.
4. Baviera AM, Zanon NM, Navegantes LC, Kettelhut IC. Involvement of cAMP/Epac/PI3K-dependent pathway in the antiproteolytic effect of epinephrine on rat skeletal muscle. Mol Cell Endrocrinol 315: 104-112, 2010.
5. Beauchard A, Ferandin Y, Fregrave;re S, Lozach O, Blairvacq M, Meijer L, Thiery V, Besson T. Synthesis of novel 5-substituted indirubins as protein kinases. Bioorg Med Chem 14: 6434-6443, 2006.
6. Bernstein H, Payne CM, Bernstein C, Schneider J, Beard SE, Crowley CL. Activation of the promoters of genes associated with DNA damage, oxidative stress, ER stress and protein malfolding by the bile salt, deoxycholate. Toxicol Lett 108: 37-46, 1999.
7. Beurel E, Jope RS. The paradoxical pro- and antiapoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79: 173-189, 2006.
8. Bijur GN, Jope RS. Glycogen synthase kinase-3 beta is highly active in nuclei and mitochondria. Neuroreport 14: 2415-2419, 2003.
9. Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, Kaestner KH. Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat Med 14: 828-836, 2008.
10. Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, Lemasters JJ. The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. Mol Cell Biol 18: 6353-6364, 1998.
11. Breckler M, Berthouze M, Laurent AC, Crozatier B, Morel E, Lezoualch F. Rap-linked cAMP signaling Epac proteins: Compartmentation, functioning and disease implications. Cell Signal 23: 1257-1266, 2011.
12. Carboni S, Hiver A, Szyndralewiez C, Gaillard P, Gotteland JP, Vitte PA. AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther 310: 25-32, 2004.
13. Cleary JM, Shapiro GI. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep 12: 87-94, 2010.
14. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder JC. Selective small molecular inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7: 793-803, 2000.
15. Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 77: 94-102, 2001.
16. Cullen KA, McCool J, Anwer MS, Webster CR. Activation of cAMPguanine exchange factor confers PKA-independent protection from hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol 287: G334- G343, 2004.
17. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM, Louhelainen M, Foster SJ, Yaqoob MM, Thiemermann C. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 33: 1903-1912, 2005.
18. Engelman JA. Targeting PI3K signaling in cancer: opportunities, challenges, and limitations. Nat Rev Cancer 9: 550-562, 2009.
19. Fischer L, Gukovskaya AS, Penninger JM, Mareninova OA, Friess H, Gukovsky I, Pandol SJ. Phosphatidylinositol 3-kinase facilitates bile acid-induced Ca2 responses in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol 292: G875-G886, 2007.
20. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 64: 1930-1944, 2007.
21. Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci 10: 481-494, 2009.
22. Gates A, Hohenester S, Anwer MS, Webster CR. cAMP-GEF cytoprotection by Src tyrosine kinase activation of phosphoinositide-3-kinase p110 _/_ in rat hepatocytes. Am J Physiol Gastrointest Liver Physiol 296: G764-G774, 2009.
23. Glaser S, Alvaro D, Francis H, Ueno Y, Marucci L, Benedetti A, De Morrow S, Marzioni M, Mancino MG, Phinizy JL, Reichenbach R, Fava G, Summers R, Venter J, Alpini G. Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. Am J Physiol Gastrointest Liver Physiol 290: G813-G826, 2006.
24. Gloerich M, Bos JL. Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 50: 355-375, 2010.
25. Graf D, Reinehr R, Kurz AK, Fischer R, Hadie;ussinger D. Inhibition of taurolithocholate 3-sulfate induced apoptosis by cyclic AMP in rat hepatocytes involves protein kinase A dependent and independent mechanism. Arch Biochem Biophys 415: 34-42, 2003.
26. Grambihler A, Higuchi H, Bronk SF, Gores GJ. cFLIP-L inhibits p38 MAPK activation: an additional anti-apoptotic mechanism in bile acidmediated apoptosis. J Biol Chem 278: 26831-26837, 2001.
27. Henderson NC, Pollock KJ, Frew J, Mackinnon AC, Flavell RA, Davis RJ, Sethi T, Simpson KJ. Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure. Gut 56: 982-990, 2007.
28. Hernaacute;ndez F, de Barreda EG, Fuster-Matanzo A, Gontild;i-Oliver P, Lucas JJ, Avila J. The role of GSK3 in Alzheimers disease. Brain Res Bull 80: 248-250, 2009.
29. Hernaacute;ndez F, Nido JD, Avila J, Villanueva N. GSK3 inhibitors and disease. Mini Rev Med Chem 9: 1024-1029, 2009.
30. Higuchi H, Bronk SF, Takikawa Y, Werneburg N, Takimoto R, El-Deiry W, Gores GJ. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem 276: 38610- 36808, 2001.
31. Higuchi H, Miyoshi H, Bronk SF, Zhang H, Dean N, Gores GJ. Bid antisense attenuates bile acid induced apoptosis and cholestatic liver injury. J Pharmacol Exp Ther 299: 866-873, 2001.
32. Higuchi H, Yoon JH, Grambihler A, Werneburg N, Bronk SF, Gores GJ. Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. J Biol Chem 278: 454-461, 2003.
33. Holz GG, Chepurny OG, Schwede F. Epac selective cAMP analogues: new tools with which to evaluate the signal transduction properties of cAMP-regulated quinine nucleotide exchange factors. Cell Signal 20: 10-20, 2008.
34. Hohenester S, Gates A, Wimmer R, Beuers U, Anwer MS, Rust C, Webster CR. Phosphatidylinositol-3-kinase p110 gamma contributes to bile salt induced apoptosis in primary rat hepatocytes and human hepatoma cells. J Hepatol 53: 918-926, 2010.
35. Ibrahim SH, Akazawa Y, Cazanave SC, Bronk SF, Elmi NA, Werneburg NW, Billadeau DD, Gores GJ. Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. J Hepatol 54: 765-772, 2011.
36. Jensen J, Brennesvik EO, Lai YC, Shepherd PR. GSK-3beta regulation in skeletal muscles by adrenaline and insulin: evidence that PKA and PKB regulate different pools of GSK-3. Cell Signal 19: 204-210, 2007.
37. Jeyaraj SC, Unger NT, Chotani MA. Rap1 GTPases: an emerging role in the cardiovasculature. Life Sci 88: 645-652, 2011.
38. Jope RS, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102, 2004.
39. Juhaszova M, Zoroy DB, Yaniv Y, Nuss HB, Wang S, Sollot SJ. Role of glycogen synthase kinase 3-beta in cardioprotection. Circ Res 104: 1240-1252, 2009.
40. Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH, Colmenero J, Bataller R, Schwabe RF. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138: 347-359, 2010.
41. Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase 3 an overview of an over-achieving kinase. Curr Drug Targets 7: 1377-1388, 2009.
42. Kodama Y, Taura K, Miura K, Schnabl B, Osawa Y, Brenner DA. Antiapoptotic effect of c-Jun N-terminal kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. Gastroenterology 136: 1423-1434, 2009.
43. Kwak HJ, Park KM, Choi HE, Chung KS, Lim HJ, Park HY. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Cell Signal 20: 803-814, 2008.
44. Kwon G, Pappan KL, Marshall CA, Schaffer JE, McDaniel ML. cAMP dose dependently prevents palmitate induced apoptosis by both protein kinase A and cAMP guanine nucleotide exchange factor dependent pathways in beta-cells. J Biol Chem 279: 8938-8945, 2004.
45. Lam P, Soroka CJ, Boyer JL. The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease. Semin Liver Dis 30: 125-133, 2010.
46. Leist M, Volbracht C, Fava E, Nicotera P. 1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis. Mol Pharmacol 54: 789-801, 1998.
47. Liedtke C, Trautwein C. The role of JNK2 in toxic liver injury. J Hepatol 45: 762-764, 2006.
48. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3_, mood stabilizers and neuroprotection. Bipolar Disord 4: 137-144, 2002.
49. Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA, Bouchard RJ, Florezmccre ML, Heidenreich KA. Glycogen synthase kinase 3 beta phosphorylates Bax and promotes it mitochondrial localization during neuronal apoptosis. J Neurosci 24: 9993-10002, 2004.
50. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol 54: 795-809, 2011.
51. Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev 90: 1165-1194, 2010.
52. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760, 2006.
53. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, Crovace C, Tarricone C, Musacchio A, Roe SM, Pearl L, Greengard P. GSK-3 selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10: 1255-1266, 2003.
54. Mencin A, Seki E, Osawa Y, Kodama Y, De Minicis S, Knowles M, Brenner DA. Alpha antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis. Hepatology 46: 1443-1452, 2007.
55. Misra UK, Kaczowka S, Pizzo SV. The cAMP-activated GTP exchange factor, Epac1 upregulates plasma membrane and nuclear Akt kinase activities in 8-CPT-2-O-Me-cAMP-stimulated macrophages: gene silencing of the cAMP-activated GTP exchange Epac1 prevents 8-CPT-2-OMe- cAMP activation of Akt activity in macrophages. Cell Signal 20: 1459-1470, 2008.
56. Mitchell C, Park MA, Zhang G, Han SI, Harada H, Franklin RA. 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines. Mol Cancer Ther 6: 618-632, 2007.
57. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 117: 669-677, 1999.
58. Muira T, Miki T. GSK-3 beta, a therapeutic target for cardiomyocyte protection. Circ J 73: 1184-1192, 2009.
59. Nalapareddy P, Schudie;ngel S, Hong JY, Manns MP, Jaeschke H, Vogel A. The BH3 protein bid does not mediate death receptor induced liver injury in obstructive cholestasis. Am J Pathol 175: 1077-1085, 2009.
60. Namkoong S, Kim CK, Cho YL, Lee H, Ha KS, Choe J, Kim PH, Won MH, Kown YG, Shim EB, Kim YM. Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling. Cell Signal 21: 906-915, 2009.
61. Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 21: 44-58, 2011.
62. Nijholt IM, Dolga AM, Ostroveanu A, Luiten PG, Schmidt M, Eisel UL. Neuronal AKAP150 coordinates PKA and Epac-mediated PKB/Akt phosphorylation. Cell Signal 20: 1715-1724, 2008.
63. Nitta T, Kim JS, Mohunczy D, Behrns KE. Murine cirrhosis induces hepatocytes epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 48: 909-919, 2008.
64. Ohori K, Miura T, Tanno M, Miki T, Sato T, Ishikawa S, Horio Y, Shimamoto K. Ser9 phosphorylation of mitochondrial GSK3_ is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant induced apoptosis. Am J Physiol Heart Circ Physiol 295: H2079-H2086, 2008.
65. Perez MJ, Briz O. Bile acid induced cell injury and protection. World J Gastroenterol 15: 1677-1689, 2009.
66. Perez DI, Conde S, Perez C, Gil S, Simon D, Wandosell F, Moreno FJ, Gelpi JL, Lugue FJ, Martinez A. Thienylhalomethylketones: irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorg Med Chem 57: 6914-6925, 2009.
67. Ponzetti K, King M, Gates A, Anwer SA, Webster CRL. Cyclic AMP-guanine exchange factor activation inhibits JNK dependent lipopolysaccharide induced apoptosis in rat hepatocytes [Online]. Hepatic Medicine: Evidence and Research http://www.dovepress.com/cyclic-ampguanine-exchange-factor-activation-inhibits-jnk-dependent-l-peerreviewed-article-HMER, [3 July 2010].
68. Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN. GSK3beta: a role in therapeutic landscape and development of modulators. Br J Pharmacol 60: 1-19, 2010.
69. Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W, Molkentin J, Schmidt-Ullrich R, Fisher PB, Grant S, Hylemon PB, Dent P. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen activated protein kinase signaling kinase signaling module enhances DCA induced apoptosis. Mol Biol Cell 12: 2629-2645, 2001.
70. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3; more than a namesake. Br J Pharmacol 156: 885-898, 2009.
71. Reinehr R, Hadie;ussinger D. Inhibition of bile salt induced apoptosis by cyclic AMP involves serine/threonine phosphorylation of CD95. Gastroenterology 126: 249-262, 2004.
72. Reinehr R, Becker S, Wettstein M, Hadie;ussinger D. Involvement of the Src family kinase yes in bile salt induced apoptosis. Gastroenterology 127: 1540-1557, 2004.
73. Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species. Mol Med 4: 165-178, 1998.
74. Rust C, Wild N, Bernt C, Vennegeerts T, Wimmer R, Beuers U. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid induced apoptosis via activation of survival pathways. Bile acid induced apoptosis in hepatocytes is caspase-6-dependent. J Biol Chem 284: 2908-2916, 2009.
75. Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, Haisma HJ, Jensen PL, Moshage H. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 39: 1563-1573, 2004.
76. Schoemaker MH, Gommans WM, Conde de la Rosa L, Homan M, Klok P, Trautwein C, van Goor H, Poelstra K, Haisma HJ, Jansen PL, Moshage H. Resistance of rat hepatocytes against bile acid induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol 39: 153-161, 2003.
77. Schulze-Bergkamen H, Brenner D, Krueger A, Suess D, Fas SC, Frey CR, Dax A, Zink D, Budie;chler P, Mudie;ller M, Krammer PH. Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology 39: 645-654, 2004.
78. Shinohara M, Ybanez MD, Win S, Than TA, Jain S, Gaarde WA, Han D, Kaplowitz N. Silencing of glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid leukemia sequence 1. J Biol Chem 285: 8244-8255, 2010.
79. Shore GC, Papa FR, Oakes SA. Signaling cell death from the endoplasmic reticulum stress response. Curr Opin Cell Biol 23: 1-7, 2010.
80. Sinclair EM, Yusta B, Streutker C, Baggio LL, Koehler J, Charron MJ, Drucker DJ. Glucagon receptor signaling is essential for control of murine hepatocyte survival. Gastroenterology 135: 2096-2106, 2008.
81. Smith DG, Buffet M, Fenwick AE, Haigh D, Ife RJ, Saunders M, Slingsby BP, Stacey R, Ward RW. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett 11: 635-639, 2001.
82. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of Ikappa- Balpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 279: 39541-39554, 2003.
83. Tamaki N, Hatano E, Taura K, Tada M, Kodama Y, Nitta T, Iwaisako K, Seo S, Nakajima A, Ikai I, Uemoto S. CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury. Am J Physiol Gastrointest Liver Physiol 294: G498-G505, 2008.
84. Theruvath TP, Czerny C, Ramshesh VK, Zhong Z, Chavin KD, Lemasters JJ. C-Jun N-terminal kinase 2 promotes graft injury via the mitochondrial permeability transition after mouse liver transplantation. Am J Transplant 8: 1819-1828, 2008.
85. Theruvath TP, Snoddy MC, Zhong Z, Lemasters JJ. Mitochondrial permeability transition in liver ischemia and reperfusion: role of c-Jun N-terminal kinase 2. Transplantation 85: 1500-1504, 2008.
86. Tsuchiya S, Tsuji M, Morio Y, Oguchi K. Involvement of endoplasmic reticulum in glycochenodeoxycholic acid-induced apoptosis in rat hepatocytes. Toxicol Lett 166: 140-149, 2006.
87. Varela AT, Simoes AM, Teodoro JS, Gomes AP, Palmeira CM, Rolo AP. Indirubin-3=-oxime prevents hepatic I/R damage by inhibiting GSK-3 and mitochondrial permeability transition. Mitochondrion 10: 456-463, 2010.
88. Wada A. GSK-3 inhibitors and insulin receptor signaling in health, disease and therapeutics. Front Biosci 14: 1558-1570, 2009.
89. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol 51: 565-580, 2009.
90. Wang Y, Huang WC, Wang CY, Tsai CC, Chen CL, Chang YT, Kai JI, Lin CF. Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis. Br J Pharmacol 157: 1004-1013, 2009.
91. Wang Y, Singh R, Lefkowitch JH, Rigoli RM, Czaja MJ. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem 281: 15258-15267, 2006.
92. Webster CR, Anwer MS. Phosphoinositide 3-kinase, but not mitogenactivated protein kinase, pathway is involved in hepatocyte growth factormediated protection against bile acid-induced apoptosis in cultured rat hepatocytes. Hepatology 33: 608-615, 2001.
93. Webster CR, Usechak P, Anwer MS. cAMP inhibits bile acid induced apoptosis by blocking caspase activation and cytochrome C release. Am J Physiol Gastrointest Liver Physiol 283: G727-G738, 2002.
94. Webster CR, Srinivasulu U, Ananthanarayanan M, Suchy FJ, Anwer MS. Protein kinase B/Akt mediates cAMP and cell swelling stimulated Na/taurocholate cotransport and Ntcp translocation. J Biol Chem 277: 28578-28583, 2002.
95. Wittchen ES, Worthylake RA, Kelly P, Casey PJ, Quilliam LA, Burridge K. Rap1 GTPase inhibits leukocyte transmigration by promoting endothelial barrier function. J Biol Chem 280: 11675-11682, 2005.
96. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20: 87-90, 2010.
97. Yano N, Suzuki D, Endoh M, Zhao TC, Padbury JF, Tseng YT. A novel phosphoinositide 3-kinase-dependent pathway for angiotensin II/ AT-1 receptor-mediated induction of collagen synthesis in MES-13 mesangial cells. J Biol Chem 282: 18819-18830, 2007.
98. Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid induced apoptosis and autophagy in primary hepatocytes via p53-CD95 dependent signaling. J Biol Chem 283: 24343-24358, 2008.